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Abstract
Background and Aims: Hemorrhoid disorders are common. 
This study aimed to assess the efficacy and safety of polido-
canol foam injected at high doses with intravenous needle 
for the treatment of symptomatic internal hemorrhoids that 
prolapse or bleed. Methods: We evaluated 2,000 consecu-
tive patients with prolapsed hemorrhoids (grades II/III/IV) re-
cruited over 6 years. Foam injection was performed in one 
to four sessions with polidocanol 2%: 10 mL of the mixture 
(2 mL liquid plus air) or 20 mL (4 mL liquid plus air). The num-
ber of sessions and amount of foam injected depended on 
initial hemorrhoid size, compliance to receive foam, and clin-
ical response. The mixture, prepared using a three-way tap 
connected to two 10/20-mL syringes, was injected immedi-
ately after preparation using an intravenous needle. The pri-
mary endpoint was self-reported satisfaction without major 
complications at 4 weeks. Results: Efficacy was very high, 
with 1,957 patients (98%) reporting satisfaction regarding 
blood loss control and prolapse reduction. The procedure 
was well tolerated: 1,838 patients (92%) presented mild/no 
pain. Objective reduction of prolapse volume was docu-
mented in 86% of reobserved cases. Complications were rare 
and usually minor: only 3 cases of clinically significant bleed-
ing (0.15%), 2 of whom were on dual antiplatelet therapy 
plus oral anticoagulation, 2 cases of rectal abscess, 8 hemor-
rhoid thromboses, and 1 urinary retention requiring catheter 
(0.7% severe complications). Conclusions: Treatment of in-
ternal hemorrhoids with polidocanol foam injected in high 
doses is very effective and safe for the control of blood loss 
and prolapse, even for patients on anticoagulation/anti-
platelet treatment. © 2018 Sociedade Portuguesa de Gastrenterologia
Published by S. Karger AG, Basel
Polidocanol espumoso em doses altas injetado com 
agulha endovenosa: O tratamento (quase) perfeito 
das hemorróidas internas sintomáticas
Palavras Chave
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Resumo
Introdução e objetivo: A doença hemorroidária é muito 
vulgar. O presente estudo pretende avaliar a eficácia e a 
segurança do polidocanol espumoso em doses altas in-
jetado com agulha endovenosa no tratamento das he-
morróidas internas que prolapsam e sangram. Métodos: 
Foram avaliados 2,000 doentes consecutivos, com he-
morróidas prolapsadas (graus II/III/IV), ao longo de 6 anos. 
O polidocanol espumoso foi injetado em uma a quatro 
sessões: 10 ml de mistura (2 ml de polidocanol a 2% + ar) 
ou 20 ml de mistura (4 ml de polidocanol a 2% + ar). O 
número de sessões e a quantidade de espuma injetada 
dependeram do tamanho inicial das hemorróidas, da 
complacência durante a injeção e da resposta clínica. A 
mistura foi preparada usando uma torneira de três vias e 
duas seringas de 10/20 ml e injetada imediatamente após 
a preparação, usando uma agulha endovenosa. O objeti-
vo primário foi a satisfação avaliada pelo doente, sem 
complicações graves, 4 semanas após o tratamento. Re-
sultados: A eficácia foi muito elevada, com 1,957 doentes 
(98%) satisfeitos com a redução do prolapso e o controlo 
da hemorragia. O tratamento foi bem tolerado: 92% 
(1,838 doentes) não tiveram dor ou sofreram dor ligeira. 
A redução do prolapso foi documentada em 86% dos ca-
sos reobservados. As complicações foram raras e maiori-
tariamente ligeiras: só 3 casos sofreram hemorragia sig-
nificativa (0.15%), dois dos quais sob anticoagulação e du-
pla antiagregação; 2 casos de abcesso rectal; 8 tromboses 
hemorroidárias; e uma retenção urinária necessitando  
algaliação (complicações graves: 0.7%). Conclusões: O 
tratamento das hemorróidas internas com polidocanol 
espumoso injetado em dose elevada é eficaz, controlan-
do a hemorragia e o prolapso, e seguro, mesmo em doen-
tes sob anticoagulação/antiagregação.
© 2018 Sociedade Portuguesa de Gastrenterologia
Publicado por S. Karger AG, Basel
Introduction
Internal and external hemorrhoids are normal vascu-
lar structures [1]. External hemorrhoids manifest as a 
painful perianal swelling associated with venous throm-
bosis and less commonly hematoma. When necessary, 
anti-inflammatory drugs, ice, and blood/thrombus/ve-
nous plexus drainage are recommended therapies, but 
these procedures are beyond the scope of the present 
study [2, 3]. Internal hemorrhoids are formed by arteri-
oles, venules, and capillaries, supported by connective tis-
sue. They act as vascular cushions or “cavernous bodies” 
that swell with blood and help to seal the anal canal [4]. 
They contribute with about 10% of the basal anal pres-
sure, being important for the “fine continence” [5]. Inter-
nal hemorrhoids may present clinically as painless bleed-
ing after defecation and, when becoming bulky and pro-
lapsed (grades III/IV), can cause discomfort, burning 
sensation, pruritus, and presence of red blood in under-
wear [6, 7].
Treatment of internal hemorrhoids should only be 
performed in patients with bleeding or symptoms associ-
ated with prolapse. Treatment depends on hemorrhoid 
severity, classified in grades I–IV (position statement 
2004). Internal hemorrhoids grade I are small, do not 
prolapse, and may be fulgurated (for example using pho-
tocoagulation or argon plasma coagulation) or sclerosed 
through injection [8]. Hemorrhoids grade II only pro-
lapse with defecation effort. Elastic banding and/or scle-
rosis treatment are usually recommended. Meta-analyses 
of nonoperative therapy show that patients who undergo 
sclerotherapy have a relatively high relapse rate and that 
rubber band ligation is associated with the lowest recur-
rence rate of the nonoperative techniques [9]. Surgery is 
reserved for hemorrhoids grade III and IV that are exte-
riorized (prolapsed) [2, 10].
There are several complications of instrumental and 
surgical treatment of hemorrhoids, which may be serious 
in some patients [11–14].
Elastic banding can result in severe late bleeding, usu-
ally between days 7 and 22 after treatment in the authors’ 
experience. The more effective the banding (“pistols” 
with deep and wide cylinder, 1 × 1 cm), the bigger the ul-
cer after the band falls and the greater the bleeding risk. 
In our experience with more than 10,000 patients treated 
over a 22-year period, late bleeding occurred in almost 
4.5% of patients when two to three bands were applied per 
session (unpublished data). Pain, local discomfort, and 
tenesmus sometimes develop even when elastic bands are 
placed > 1 cm above the dentate line. Urinary retention, 
infection, and sepsis are rare complications [3, 10].
Although classical hemorrhoidectomy (Milligan-Mor- 
gan and Ferguson) is highly effective, the postoperative 
period is very painful, mainly during the first 3 weeks. 
Anal deformity, discharge, and incontinence may be im-
portant sequela. Furthermore, late bleeding, urinary re-
tention, and sepsis can also be potential adverse events [2, 
10, 12, 14].
Longo hemorrhoidopexy is less painful but also less 
effective for prolapse treatment. The most striking com-
plication is chronic persistent anal pain, which is not un-
common. The pain is thought to be associated with staple 
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placement and venous plexus dissection near the dentate 
line [15–17].
Injection of a sclerosing agent is considered poorly ef-
fective and therefore used only for small hemorrhoids. 
Liquid polidocanol 1 or 2% is commonly injected through 
the anoscope in low doses using a 1.0-mL syringe (e.g., 
insulin syringe) and a 25- to 27-G needle (e.g., subcutane-
ous needle). Experts often recommend 2 mL per session.
More than 10 years ago, we begun using polidocanol 
2% foam, which results from the mixture of liquid with 
air, changing drug characteristics with more sclerosing 
capacity and adherence to the endothelium with the same 
safety profile, but there is only one import study of its use 
and only on first-grade hemorrhoidal disease [18, 19]. We 
learned with vascular surgery that used it regularly. We 
started by gradually increasing the dose in patients with 
hemorrhoids grade II, III, and IV under oral anticoagu-
lant or double antiplatelet therapy and active bleeding. In 
these patients, there were few therapeutic options given 
the high bleeding risk associated with surgery and elastic 
banding. We verified that it was an extremely safe and ef-
fective procedure. Furthermore, we increased the dose 
and used an intravenous needle (21-G green, intravenous 
needles) of greater caliber which made it possible to inject 
thicker and “creamy” polidocanol foam (Fig. 1). When 
preparing the foam, we need a three-way tap adapted to 
two syringes. We obtained as a gold standard the mixture 
of 2 mL polidocanol liquid with air using two 10-mL sy-
ringes or 4 mL polidocanol using two 20-mL syringes. 
Thus, a mixture of 10 mL (2 mL of liquid polidocanol 
mixed with air) or 20 mL (4 mL liquid polidocanol mixed 
with air) is injected, depending on the hemorrhoid size 
and its compliance to receive the mixture. The foamy 
polidocanol that results from the mixing of the liquid 
polidocanol with air has greater adhesion to the endothe-
lium, greater capacity of sclerosis, and greater efficacy, as 
documented in several phlebology studies, maintaining 
safety.
The present study intended to evaluate the use of poli-
docanol foam in high doses over an intravenous needle 
for the treatment of a large number of patients with symp-
tomatic internal hemorrhoids. Since grade I hemorrhoids 
are easy to treat and do not prolapse, they were not in-
cluded in this study.
Patients and Methods
We performed a prospective single-center study to evaluate the 
efficacy and safety of polidocanol foam for the treatment of symp-
tomatic internal hemorrhoids. Patients were included at a proctol-
ogy outpatient clinic of the gastroenterology department of a large 
hospital in the Lisbon area, a tertiary center for hemorrhoid ther-
apy. The study aimed to evaluate 2,000 patients. The same gastro-
enterologist treated all the patients. Inclusion criteria were: (1) age 
≥18 years; (2) internal hemorrhoids grades II, III, or IV presenting 
with hemorrhage, prolapse, or both; (3) written informed consent; 
(4) ability to fulfill the follow-up protocol. Exclusion criteria were: 
(1) age < 18 years; (2) anal fissure; (3) anal infection/suppuration; 
(4) anal pain other than caused by hemorrhoids; (5) contraindica-
tion to polidocanol use: known allergy (anaphylaxis) to polidoca-
nol.
Patients were encouraged to defecate before the procedure but 
did not under go any bowel preparation, including cleaning ene-
mas. Treatment was performed with the patient in the knee-chest 
position or lying on the left side. All treatments were performed in 
an outpatient basis and without any sedation. No prophylactic an-
tibiotics were given. All large and symptomatic hemorrhoids were 
aimed to be treated at the same session, although a second session 
might be needed.
The following were used for each patient: (1) a large adult ano-
scope; (2) polidocanol 2%, 2 mL of liquid to mix with air in order 
to obtain 10 mL of polidocanol foam, or 4 mL to mix with air in 
order to obtain 20 mL of polidocanol foam; (3) three-way tap and 
two 10-mL syringes in order to obtain 10 mL of polidocanol foam, 
or two 20-mL syringes in order to obtain 20 mL of polidocanol 
foam; (4) a 21-G needle with an extension line.
To prepare the foam, a three-way tap adapted to two syringes 
was used. A mixture of either 2 mL polidocanol liquid with air us-
ing two 10-mL syringes, or 4 mL polidocanol with air using two 
20-mL syringes was used. A mixture of 10 mL (2 mL of liquid poli-
docanol mixed with air) or 20 mL (4 mL liquid polidocanol mixed 
with air) was injected, depending on the size of the hemorrhoid 
and its compliance to receive the mixture. It was very easy to man-
age the two syringes. The liquid was placed in a syringe, in the 
other the amount of air we wanted. The three-way tap was used for 
mixing.
Fig. 1. Preparation of polidocanol foam.
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With the anoscope introduced, the hemorrhoid to be treated 
was clearly identified. The polidocanol foam was prepared in the 
treatment room and was injected immediately after being pre-
pared. Delay may decrease foam volume, allow for liquid accumu-
lation, and potentially reduced efficacy. The polidocanol foam was 
injected above the dentate line. Each hemorrhoid was injected 
once, in several directions and at variable depths, until the hemor-
rhoid turned larger and whitish. A small, self-limited bleed was 
common.
After the procedure, patients were allowed to use paracetamol 
as needed for pain or discomfort control. They received the physi-
cian’s direct phone number and were instructed to report any 
problem. In the first and fourth week after treatment, all patients 
were contacted by phone.
Success was defined as self-reported reduction or disappear-
ance of bleeding and prolapse at 4 weeks, without major complica-
tions. Complications were defined as follows: (1) Minor complica-
tions: (a) postprocedure pain was defined as mild, moderate, or 
intense, treated with paracetamol/NSAIDs without need for hos-
pital admission. (2) Major complications: (a) clinically significant 
bleeding defined as the need for any of the following: blood trans-
fusion, in-hospital admission, or antiplatelet/anticoagulation sus-
pension; (b) severe pain requiring hospital admission; (c) urinary 
retention with need for urinary catheter placement; (d) unplanned 
hemorrhoid surgery on follow-up.
Results
A total of 2,000 consecutive patients treated with poli-
docanol foam were included (Table 1) between January 
2012 and August 2017, with ages ranging from 22 to 94 
years (mean age 54 years); 1,162 of them were males 
(58%). The shortest follow-up was 4 months. Hemor-
rhoid grade had the following distribution: grade II, 1,222 
patients (61%); grade III, 577 patients (29%); grade IV, 
201 patients (10%).
A total of 210 patients (10.5%) were taking anticoagu-
lants or double antiplatelet therapy: 92 patients were un-
der antiplatelet therapy with two antiplatelet drugs, 96 
patients were under anticoagulation, and 22 patients were 
simultaneously under anticoagulation and antiplatelet 
therapy. For this study, patients taking only one antiplate-
let agent were not considered as having an increased 
bleeding risk.
The number of treatment sessions needed to achieve 
satisfactory clinical outcome was the following: 1,258 pa-
tients (63%) underwent 1 session; 560 patients (28%) un-
derwent 2 sessions; 182 patients (9%) underwent 3 or 4 
sessions.
At telephone follow-up, 1,957 (98%) reported to be 
“very satisfied” with the result of the treatment. The re-
ported discomfort was the following: 1,838 patients (92%) 
experienced no or slight pain controlled with paracetamol; 
124 patients (6%) reported moderately intense pain; 38 
patients (2%) suffered severe pain controlled with para- 
cetamol plus NSAIDs and not requiring hospital admis-
sion (Table 1). This was associated with either intra-anal 
hemorrhoid thrombosis or intrarectal suppuration (a 
marker of infection) with rectal tenesmus.
Surgery was performed in 10 cases (0.5%), in 8 cases to 
treat thrombosis and in 2 for suppuration. Anal suppura-
tion was only observed after the second treatment session, 
when the hemorrhoid tissue had already suffered partial 
fibrosis. Most of the cases occurred in the early phase of 
this study.
Although it was not part of the protocol, 1,112 patients 
were reexamined at their own request. Of these, 954 
(86%) had reduction of the prolapse confirmed by direct-
ed observation by the investigator (Fig. 2, 3).
Twenty-two patients were simultaneously under anti-
coagulation and antiplatelet therapy. Of these, 2 (9%) 
(both on apixaban, acetylsalicylic acid, and clopidogrel) 
suffered clinically significant bleeding, requiring in-hos-
pital admission, blood transfusion, and suspension of an-
ticoagulant therapy. Despite the bleed, these patients pre-
sented adequate fibrosis after 3 weeks. Only 1 case of clin-
Table 1. Demographic and clinical data
Baseline
Age, years (mean ± SD) 54.2±15.4
Age, years (range) 22–94
Male 1,162 (56%)
Grade
I 0
II 1,222 (61%)
III 577 (29%)
IV 201 (10%)
Antithrombotic
Single antiplatelet not reported
Dual antiplatelet 92 (4.6%)
Anticoagulation 96 (4.7%)
Antiplatelet and anticoagulation 22 (1.1%)
Four weeks
Sessions
1 1,258 (62%)
2 560 (28%)
3 or 4 186 (9.3%)
Self-assessment
Very satisfied 1,957 (98%)
Pain/discomfort
None / mild 1,838 (92%)
Moderate 124 (6%)
Severe 38 (2%)
Decreased bleeding 1,957
Significant bleeding 3 (0.15%)
Major complication 51 (2.5%)
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ically significant bleeding occurred in patients without 
anticoagulation or antiplatelet therapy (1 out of 1,790 
[0.05%]).
A few male patients complained from transient dys-
uria (at 24–48 h), but only 4 male patients (0.3%) suffered 
from transient urinary retention, and only 1 patient need-
ed Foley catheter placement.
Discussion
Hemorrhoid disorders affect almost 5% of the western 
population and are a very frequent motive for attending 
a gastroenterology outpatient clinic [10, 20]. Besides 
causing pain or discomfort and bleeding, the symptoms 
often cause apprehension, fear of cancer, and psycholog-
ical and social embarrassment. Furthermore, patients of-
ten described their complaints with shame or a sense of 
indignity.
A large number of drugs, instrumental procedures, 
and surgical interventions are used in hemorrhoid thera-
py, but their overall efficacy is only moderate, and they 
have frequent adverse side effects and complications, in 
particular with surgery [2, 10, 12, 14].
In our experience, polidocanol foam injected into the 
hemorrhoids is very effective, reducing bleeding and pro-
lapse in 98% of patients, even in a complex population 
with 39% of patients having grade III and IV. Much larg-
er amounts than usual (10 or 20 mL of the mixture) may 
be applied when polidocanol is used with liquid. Internal 
hemorrhoids (arterioles and veins, supported by connec-
tive tissue) function as a cushion/pillow (corpus caverno-
sum) with compliance to receive 10 mL, 20 mL, or more 
of foamy polidocanol, depending on the size/compliance. 
In our experience, we have documented greater effective-
ness with high doses and safety. Also, it is a very safe ther-
apy, with only 0.7% of serious complications, such as ma-
jor bleeding, urinary retention, or infection/suppuration 
requiring surgery. The therapeutic thrombosis and fibro-
sis of internal hemorrhoids induced by polidocanol foam 
is very well tolerated, as it progresses without clinically 
significant symptoms in the large majority of patients – 
only 2% reported severe pain, which was controlled with 
paracetamol plus NSAIDs.
Polidocanol foam proved to be effective and safe even 
for patients under anticoagulation/antiplatelet therapy. 
For these patients, polidocanol foam is our preferred 
therapy, as it does not require any adjustment or inter-
Fig. 2. Before and after treatment.
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Fig. 3. Prolapse reduction after treatment.
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ruption of the anticoagulation/antiplatelet therapy and 
was associated with acceptable bleeding rates. Only 3 out 
of 2,000 patients (0.15%) presented clinically significant 
bleeding, and all were easily managed. Two of them were 
simultaneously under anticoagulation and antiplatelet 
therapy. Eventually, the patients under this association 
may need a closer follow-up after the procedure. Clearly, 
polidocanol foam is the therapy of choice. For these pa-
tients, the liquid form of polidocanol is poorly effective. 
Ligation and surgery are at high risk for late-onset bleed-
ing. In this group of patients, we recommend polidocanol 
foam because it is very effective and the risk of bleeding 
is acceptable (low), and there are no other options if we 
want to keep up antiplatelet therapy/anticoagulation.
Other complications, such as transient urinary reten-
tion, were very rare, reported in only 0.3% of males. There 
were no cases of embolism in our experience. Foamy poli-
docanol adheres to the endothelium, provoking inflam-
matory response and sclerosis. Furthermore, vascular 
surgeons inject the foamy polidocanol directly into the 
external saphenous vein, and this is considered a very safe 
procedure.
Serious complications arose after the second treat-
ment session and seem to have been due to a too deep or 
forced injection of the foam. Most of them occurred at the 
beginning of the study, evidencing the need for a progres-
sive learning curve with this technique, in particular when 
performing repeated therapeutic sessions. It is advisable 
to inject the foam only in soft hemorrhoids. The suppura-
tions arose as a complication in an early phase of the 
study: they were due to the forced and deep injection. The 
injection has to be into the submucosa. Hemorrhoids 
have compliance. Polidocanol foam should not be inject-
ed deeply or forced if fibrosis already exists (previously 
treated hemorrhoids). Any deep or forced injection 
should be avoided, in particular in previously treated 
hemorrhoids, which may lead to foam injection into the 
deep muscular layers, into the prostate, or into the semi-
nal vesicles. Carefully used, polidocanol foam is very safe. 
It should be stressed that complete patient information is 
mandatory and that, after the procedure, the physician 
must be easily available for the patient’s doubts or proce-
dure complications.
Conclusions
Polidocanol foam therapy of symptomatic hemor-
rhoid diseases is very safe. It does not need any special 
bowel preparation, sedation, or pain control, and it can 
be performed on an outpatient basis. Polidocanol foam 
should be used as first-line treatment of most hemorrhoid 
patient, including those under anticoagulation and anti-
platelet therapy. Gastroenterologists, surgeons, and proc-
tologists who usually perform therapeutic treatment of 
benign proctologic lesions should become proficient with 
this technique.
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